arXiv:2601.10718v1 Announce Type: new Abstract: Human papillomavirus (HPV) vaccine hesitancy poses significant public health challenges, particularly in Japan where proactive vaccination recommendations were suspended from 2013 to 2021. The resulting information gap is exacerbated by misinformation on social media, and traditional ways cannot simultaneously address individual queries while monitoring population-level discourse. This study aimed to develop a dual-purpose AI agent system that provides verified HPV vaccine information through a conversational interface while generating analytical reports for medical institutions based on user interactions and social media. We implemented a system comprising: a vector database integrating academic papers, government sources, news media, and social media; a Retrieval-Augmented Generation chatbot using ReAct agent architecture with multi-tool orchestration across five knowledge sources; and an automated report generation system with modules for news analysis, research synthesis, social media sentiment analysis, and user interaction pattern identification. Performance was assessed using a 0-5 scoring scale. For single-turn evaluation, the chatbot achieved mean scores of 4.83 for relevance, 4.89 for routing, 4.50 for reference quality, 4.90 for correctness, and 4.88 for professional identity (overall 4.80). Multi-turn evaluation yielded higher scores: context retention 4.94, topic coherence 5.00, and overall 4.98. The report generation system achieved completeness 4.00-5.00, correctness 4.00-5.00, and helpfulness 3.67-5.00, with reference validity 5.00 across all periods. This study demonstrates the feasibility of an integrated AI agent system for bidirectional HPV vaccine communication. The architecture enables verified information delivery with source attribution while providing systematic public discourse analysis, with a transferable framework for adaptation to other medical contexts.

arXiv:2601.10748v1 Announce Type: cross Abstract: Background: Artificial intelligence enabled electrocardiography (AI-ECG) has demonstrated the ability to detect diverse pathologies, but most existing models focus on single disease identification, neglecting comorbidities and future risk prediction. Although ECGFounder expanded cardiac disease coverage, a holistic health profiling model remains needed. Methods: We constructed a large multicenter dataset comprising 13.3 million ECGs from 2.98 million patients. Using transfer learning, ECGFounder was fine-tuned to develop AnyECG, a foundation model for holistic health profiling. Performance was evaluated using external validation cohorts and a 10-year longitudinal cohort for current diagnosis, future risk prediction, and comorbidity identification. Results: AnyECG demonstrated systemic predictive capability across 1172 conditions, achieving an AUROC greater than 0.7 for 306 diseases. The model revealed novel disease associations, robust comorbidity patterns, and future disease risks. Representative examples included high diagnostic performance for hyperparathyroidism (AUROC 0.941), type 2 diabetes (0.803), Crohn disease (0.817), lymphoid leukemia (0.856), and chronic obstructive pulmonary disease (0.773). Conclusion: The AnyECG foundation model provides substantial evidence that AI-ECG can serve as a systemic tool for concurrent disease detection and long-term risk prediction.

arXiv:2601.10951v1 Announce Type: cross Abstract: The simulation of realistic clinical interactions plays a pivotal role in advancing clinical Large Language Models (LLMs) and supporting medical diagnostic education. Existing approaches and benchmarks rely on generic or LLM-generated dialogue data, which limits the authenticity and diversity of doctor-patient interactions. In this work, we propose the first Chinese patient simulation dataset (Ch-PatientSim), constructed from realistic clinical interaction scenarios to comprehensively evaluate the performance of models in emulating patient behavior. Patients are simulated based on a five-dimensional persona structure. To address issues of the persona class imbalance, a portion of the dataset is augmented using few-shot generation, followed by manual verification. We evaluate various state-of-the-art LLMs and find that most produce overly formal responses that lack individual personality. To address this limitation, we propose a training-free Multi-Stage Patient Role-Playing (MSPRP) framework, which decomposes interactions into three stages to ensure both personalization and realism in model responses. Experimental results demonstrate that our approach significantly improves model performance across multiple dimensions of patient simulation.

arXiv:2601.11505v1 Announce Type: cross Abstract: Progress in Type 1 Diabetes (T1D) algorithm development is limited by the fragmentation and lack of standardization across existing T1D management datasets. Current datasets differ substantially in structure and are time-consuming to access and process, which impedes data integration and reduces the comparability and generalizability of algorithmic developments. This work aims to establish a unified and accessible data resource for T1D algorithm development. Multiple publicly available T1D datasets were consolidated into a unified resource, termed the MetaboNet dataset. Inclusion required the availability of both continuous glucose monitoring (CGM) data and corresponding insulin pump dosing records. Additionally, auxiliary information such as reported carbohydrate intake and physical activity was retained when present. The MetaboNet dataset comprises 3135 subjects and 1228 patient-years of overlapping CGM and insulin data, making it substantially larger than existing standalone benchmark datasets. The resource is distributed as a fully public subset available for immediate download at https://metabo-net.org/ , and with a Data Use Agreement (DUA)-restricted subset accessible through their respective application processes. For the datasets in the latter subset, processing pipelines are provided to automatically convert the data into the standardized MetaboNet format. A consolidated public dataset for T1D research is presented, and the access pathways for both its unrestricted and DUA-governed components are described. The resulting dataset covers a broad range of glycemic profiles and demographics and thus can yield more generalizable algorithmic performance than individual datasets.

npj Digital Medicine, Published online: 17 January 2026; doi:10.1038/s41746-026-02344-8

Wearable device derived electrocardiographic age and its association with atrial fibrillation

The startup has partnered with Eli Lilly and enjoys the backing of some of Silicon Valley's most influential VCs.

AI companies are clustering around healthcare and fast.  In just the past week, OpenAI bought health startup Torch, Anthropic launched Claude for healthcare, and Sam Altman-backed MergeLabs closed a $250 million seed round at an $850 million valuation. The money and products are pouring into health and voice AI, but so are concerns about hallucination risks, inaccurate medical information, and […]

This is the online version of Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.

A chill week

No M&A. Some news but not a deluge. The weather was amazing. I took a walk in Golden Gate Park and came across the sculpture above, whatever it is. 

The entire week was, dare I say it, chill. Just the way I wanted it to be. 

Continue to STAT+ to read the full story…

© Josh Edelson/AFP/Getty Images

Nature Cancer, Published online: 16 January 2026; doi:10.1038/s43018-025-01110-1

Yabut and Drucker discuss clinical and preclinical evidence about the potential roles of GLP-1 medicines on cancer incidence, development and therapy and speculate about their mechanism on cancer cells and the tumor microenvironment.

Nature Medicine, Published online: 16 January 2026; doi:10.1038/s41591-025-04073-z

Analyses of liver biopsies from a child with spinal muscular atrophy treated with adeno-associated virus gene therapy who developed hepatitis reveal contaminating manufacturing plasmids and disrupted vector genomes, possibly resulting from recombination events.

OpenAI, Google, and Anthropic announced specialised medical AI capabilities within days of each other this month, a clustering that suggests competitive pressure rather than coincidental timing. Yet none of the releases are cleared as medical devices, approved for clinical use, or available for direct patient diagnosis—despite marketing language emphasising healthcare transformation.

OpenAI introduced ChatGPT Health on January 7, allowing US users to connect medical records through partnerships with b.well, Apple Health, Function, and MyFitnessPal. Google released MedGemma 1.5 on January 13, expanding its open medical AI model to interpret three-dimensional CT and MRI scans alongside whole-slide histopathology images. 

Anthropic followed on January 11 with Claude for Healthcare, offering HIPAA-compliant connectors to CMS coverage databases, ICD-10 coding systems, and the National Provider Identifier Registry.

All three companies are targeting the same workflow pain points—prior authorisation reviews, claims processing, clinical documentation—with similar technical approaches but different go-to-market strategies.

Developer platforms, not diagnostic products

The architectural similarities are notable. Each system uses multimodal large language models fine-tuned on medical literature and clinical datasets. Each emphasises privacy protections and regulatory disclaimers. Each positions itself as supporting rather than replacing clinical judgment.

The differences lie in deployment and access models. OpenAI’s ChatGPT Health operates as a consumer-facing service with a waitlist for ChatGPT Free, Plus, and Pro subscribers outside the EEA, Switzerland, and the UK. Google’s MedGemma 1.5 releases as an open model through its Health AI Developer Foundations program, available for download via Hugging Face or deployment through Google Cloud’s Vertex AI. 

Anthropic’s Claude for Healthcare integrates into existing enterprise workflows through Claude for Enterprise, targeting institutional buyers rather than individual consumers. The regulatory positioning is consistent across all three. 

OpenAI states explicitly that Health “is not intended for diagnosis or treatment.” Google positions MedGemma as “starting points for developers to evaluate and adapt to their medical use cases.” Anthropic emphasises that outputs “are not intended to directly inform clinical diagnosis, patient management decisions, treatment recommendations, or any other direct clinical practice applications.”

Benchmark performance vs clinical validation

Medical AI benchmark results improved substantially across all three releases, though the gap between test performance and clinical deployment remains significant. Google reports that MedGemma 1.5 achieved 92.3% accuracy on MedAgentBench, Stanford’s medical agent task completion benchmark, compared to 69.6% for the previous Sonnet 3.5 baseline. 

The model improved by 14 percentage points on MRI disease classification and 3 percentage points on CT findings in internal testing. Anthropic’s Claude Opus 4.5 scored 61.3% on MedCalc medical calculation accuracy tests with Python code execution enabled, and 92.3% on MedAgentBench. 

The company also claims improvements in “honesty evaluations” related to factual hallucinations, though specific metrics were not disclosed. 

OpenAI has not published benchmark comparisons for ChatGPT Health specifically, noting instead that “over 230 million people globally ask health and wellness-related questions on ChatGPT every week” based on de-identified analysis of existing usage patterns.

These benchmarks measure performance on curated test datasets, not clinical outcomes in practice. Medical errors can have life-threatening consequences, translating benchmark accuracy to clinical utility more complex than in other AI application domains.

Regulatory pathway remains unclear

The regulatory framework for these medical AI tools remains ambiguous. In the US, the FDA’s oversight depends on intended use. Software that “supports or provides recommendations to a health care professional about prevention, diagnosis, or treatment of a disease” may require premarket review as a medical device. None of the announced tools has FDA clearance.

Liability questions are similarly unresolved. When Banner Health’s CTO Mike Reagin states that the health system was “drawn to Anthropic’s focus on AI safety,” this addresses technology selection criteria, not legal liability frameworks. 

If a clinician relies on Claude’s prior authorisation analysis and a patient suffers harm from delayed care, existing case law provides limited guidance on responsibility allocation.

Regulatory approaches vary significantly across markets. While the FDA and Europe’s Medical Device Regulation provide established frameworks for software as a medical device, many APAC regulators have not issued specific guidance on generative AI diagnostic tools. 

This regulatory ambiguity affects adoption timelines in markets where healthcare infrastructure gaps might otherwise accelerate implementation—creating a tension between clinical need and regulatory caution.

Administrative workflows, not clinical decisions

Real deployments remain carefully scoped. Novo Nordisk’s Louise Lind Skov, Director of Content Digitalisation, described using Claude for “document and content automation in pharma development,” focused on regulatory submission documents rather than patient diagnosis. 

Taiwan’s National Health Insurance Administration applied MedGemma to extract data from 30,000 pathology reports for policy analysis, not treatment decisions.

The pattern suggests institutional adoption is concentrating on administrative workflows where errors are less immediately dangerous—billing, documentation, protocol drafting—rather than direct clinical decision support where medical AI capabilities would have the most dramatic impact on patient outcomes.

Medical AI capabilities are advancing faster than the institutions deploying them can navigate regulatory, liability, and workflow integration complexities. The technology exists. The US$20 monthly subscription provides access to sophisticated medical reasoning tools. 

Whether that translates to transformed healthcare delivery depends on questions these coordinated announcements leave unaddressed.

See also: AstraZeneca bets on in-house AI to speed up oncology research

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is part of TechEx and is co-located with other leading technology events. Click here for more information.

AI News is powered by TechForge Media. Explore other upcoming enterprise technology events and webinars here.

The post AI medical diagnostics race intensifies as OpenAI, Google, and Anthropic launch competing healthcare tools appeared first on AI News.

arXiv:2601.08988v1 Announce Type: new Abstract: Reliable clinical decision support requires medical AI agents capable of safe, multi-step reasoning over structured electronic health records (EHRs). While large language models (LLMs) show promise in healthcare, existing benchmarks inadequately assess performance on action-based tasks involving threshold evaluation, temporal aggregation, and conditional logic. We introduce ART, an Action-based Reasoning clinical Task benchmark for medical AI agents, which mines real-world EHR data to create challenging tasks targeting known reasoning weaknesses. Through analysis of existing benchmarks, we identify three dominant error categories: retrieval failures, aggregation errors, and conditional logic misjudgments. Our four-stage pipeline -- scenario identification, task generation, quality audit, and evaluation -- produces diverse, clinically validated tasks grounded in real patient data. Evaluating GPT-4o-mini and Claude 3.5 Sonnet on 600 tasks shows near-perfect retrieval after prompt refinement, but substantial gaps in aggregation (28--64%) and threshold reasoning (32--38%). By exposing failure modes in action-oriented EHR reasoning, ART advances toward more reliable clinical agents, an essential step for AI systems that reduce cognitive load and administrative burden, supporting workforce capacity in high-demand care settings

arXiv:2601.09072v1 Announce Type: new Abstract: Developing safe, effective, and practically useful clinical prediction models (CPMs) traditionally requires iterative collaboration between clinical experts, data scientists, and informaticists. This process refines the often small but critical details of the model building process, such as which features/patients to include and how clinical categories should be defined. However, this traditional collaboration process is extremely time- and resource-intensive, resulting in only a small fraction of CPMs reaching clinical practice. This challenge intensifies when teams attempt to incorporate unstructured clinical notes, which can contain an enormous number of concepts. To address this challenge, we introduce HACHI, an iterative human-in-the-loop framework that uses AI agents to accelerate the development of fully interpretable CPMs by enabling the exploration of concepts in clinical notes. HACHI alternates between (i) an AI agent rapidly exploring and evaluating candidate concepts in clinical notes and (ii) clinical and domain experts providing feedback to improve the CPM learning process. HACHI defines concepts as simple yes-no questions that are used in linear models, allowing the clinical AI team to transparently review, refine, and validate the CPM learned in each round. In two real-world prediction tasks (acute kidney injury and traumatic brain injury), HACHI outperforms existing approaches, surfaces new clinically relevant concepts not included in commonly-used CPMs, and improves model generalizability across clinical sites and time periods. Furthermore, HACHI reveals the critical role of the clinical AI team, such as directing the AI agent to explore concepts that it had not previously considered, adjusting the granularity of concepts it considers, changing the objective function to better align with the clinical objectives, and identifying issues of data bias and leakage.

arXiv:2601.09152v1 Announce Type: new Abstract: This paper introduces PRA, an AI-agent design for simulating how individual users form privacy concerns in response to real-world news. Moving beyond population-level sentiment analysis, PRA integrates privacy and cognitive theories to simulate user-specific privacy reasoning grounded in personal comment histories and contextual cues. The agent reconstructs each user's "privacy mind", dynamically activates relevant privacy memory through a contextual filter that emulates bounded rationality, and generates synthetic comments reflecting how that user would likely respond to new privacy scenarios. A complementary LLM-as-a-Judge evaluator, calibrated against an established privacy concern taxonomy, quantifies the faithfulness of generated reasoning. Experiments on real-world Hacker News discussions show that \PRA outperforms baseline agents in privacy concern prediction and captures transferable reasoning patterns across domains including AI, e-commerce, and healthcare.

arXiv:2601.08838v1 Announce Type: cross Abstract: Large-scale Text-to-SQL benchmarks such as BIRD typically assume complete and accurate database annotations as well as readily available external knowledge, which fails to reflect common industrial settings where annotations are missing, incomplete, or erroneous. This mismatch substantially limits the real-world applicability of state-of-the-art (SOTA) Text-to-SQL systems. To bridge this gap, we explore a database-centric approach that leverages intrinsic, fine-grained information residing in relational databases to construct missing evidence and improve Text-to-SQL accuracy under annotation-scarce conditions. Our key hypothesis is that when a query requires multi-step reasoning over extensive table information, existing methods often struggle to reliably identify and utilize the truly relevant knowledge. We therefore propose to "cache" query-relevant knowledge on the database side in advance, so that it can be selectively activated at inference time. Based on this idea, we introduce Companion Agents (CA), a new Text-to-SQL paradigm that incorporates a group of agents accompanying database schemas to proactively mine and consolidate hidden inter-table relations, value-domain distributions, statistical regularities, and latent semantic cues before query generation. Experiments on BIRD under the fully missing evidence setting show that CA recovers +4.49 / +4.37 / +14.13 execution accuracy points on RSL-SQL / CHESS / DAIL-SQL, respectively, with larger gains on the Challenging subset +9.65 / +7.58 / +16.71. These improvements stem from CA's automatic database-side mining and evidence construction, suggesting a practical path toward industrial-grade Text-to-SQL deployment without reliance on human-curated evidence.

arXiv:2601.08841v1 Announce Type: cross Abstract: The increasing volume and complexity of scientific literature demand robust methods for organizing and understanding research documents. In this study, we explore how structured knowledge, specifically, subject-predicate-object triples, can enhance the clustering and classification of scientific papers. We propose a modular pipeline that combines unsupervised clustering and supervised classification over multiple document representations: raw abstracts, extracted triples, and hybrid formats that integrate both. Using a filtered arXiv corpus, we extract relational triples from abstracts and construct four text representations, which we embed using four state-of-the-art transformer models: MiniLM, MPNet, SciBERT, and SPECTER. We evaluate the resulting embeddings with KMeans, GMM, and HDBSCAN for unsupervised clustering, and fine-tune classification models for arXiv subject prediction. Our results show that full abstract text yields the most coherent clusters, but that hybrid representations incorporating triples consistently improve classification performance, reaching up to 92.6% accuracy and 0.925 macro-F1. We also find that lightweight sentence encoders (MiniLM, MPNet) outperform domain-specific models (SciBERT, SPECTER) in clustering, while SciBERT excels in structured-input classification. These findings highlight the complementary benefits of combining unstructured text with structured knowledge, offering new insights into knowledge-infused representations for semantic organization of scientific documents.

arXiv:2601.08869v1 Announce Type: cross Abstract: Modern artificial intelligence governance lacks a formal, enforceable mechanism for determining whether a given AI system is legally permitted to operate in a specific domain and jurisdiction. Existing tools such as model cards, audits, and benchmark evaluations provide descriptive information about model behavior and training data but do not produce binding deployment decisions with legal or financial force. This paper introduces the AI Deployment Authorisation Score (ADAS), a machine-readable regulatory framework that evaluates AI systems across five legally and economically grounded dimensions: risk, alignment, externality, control, and auditability. ADAS produces a cryptographically verifiable deployment certificate that regulators, insurers, and infrastructure operators can consume as a license to operate, using public-key verification and transparency mechanisms adapted from secure software supply chain and certificate transparency systems. The paper presents the formal specification, decision logic, evidence model, and policy architecture of ADAS and demonstrates how it operationalizes the European Union Artificial Intelligence Act, United States critical infrastructure governance, and insurance underwriting requirements by compiling statutory and regulatory obligations into machine-executable deployment gates. We argue that deployment-level authorization, rather than model-level evaluation, constitutes the missing institutional layer required for safe, lawful, and economically scalable artificial intelligence.